Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma

Anticancer Research

Volumn 20, Issue 5, 2000, Pages 3031-3036

  Morii, T ^a   Yabe, H ^a   Morioka, H ^a   Yamada, R ^a   Nakagawa, T ^a   Toyama, Y ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chondrosarcoma; Immunohistochemistry; Plasminogen activator inhibitor (PAI); Survival analysis; Urokinase type plasminogen activator (uPA); Urokinase type plasminogen activator receptor (uPAR)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RELAPSE; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHONDROSARCOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033794699     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. p53 expression and DNA ploidy of cartilage lesions
2. Immunohistochemical localization of collagenous proteins in cartilaginous tumors: Characteristic distribution of type IX collagen
3. A new parameter for judging malignancy of cartilaginous tumors using protease inhibitors immunohistochemistry
4. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas
5. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma
6. Plasminogen activators, tissue degradation, and cancer
7. Plasmin in pericellular proteolysis and cellular invasion
8. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
9. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes
10. Urokinase receptor in human malignant mesothelioma cells: Role in tumor cell mitogenesis and proteolysis
11. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
12. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma
13. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer
14. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
15. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma
16. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma
17. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study
18. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
19. Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin
20. Anti-tumor substances in cartilaginous tissue
21. Plasminogen activation in synovial tissues: Differences between normal, osteoarthritis, and rheumatoid arthritis joints
22. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees
23. Serine proteinase in articular cartilage, subchondralbone narrow and synovial fluid in human osteoarthritis and rheumatoid arthritis
24. Prognostic factors in chondrosarcoma of bone
25. Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells
26. Flow cytofluorometric analysis of the urokinase receptor(uPAR) on tumor cells by fluorescent uPA-ligand or monoclonal antibody 3936
27. Urokinase-type plasminogen activator in experimental metastasis of human osteosarcoma cells
28. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598
29. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase
30. The role of plasminogen activator receptor in cancer invasion and dormancy
31. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells
32. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells
33. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
34. Influence of intralesional surgery on treatment outcome of chondrosarcoma